InterVenn Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023

Click to copy

Press release content from Business Wire. The AP news staff was not involved in its creation.

Click to copy

InterVenn Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023

PRESS RELEASE: Paid content from Business Wire

Press release content from Business Wire. The AP news staff was not involved in its creation.

January 3, 2023 GMT

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jan 3, 2023--

InterVenn Biosciences, a life science company pioneering glycoproteomics to improve human health, today announced that senior management will present at the J.P. Morgan 41 st annual Healthcare Conference on January 11, 2023 at 8:30 a.m. Pacific.

InterVenn’s management team will be available for one-on-one meetings with investors, analysts and other interested parties during the conference.

About InterVenn Biosciences

InterVenn is a clinical technology company unlocking the value of glycoproteomics for the development of transformational healthcare solutions. The glycoproteome is a source of life-critical information about human biology that has the potential to significantly improve patient outcomes, but it has remained inaccessible due to its vast complexity. InterVenn is pioneering a new AI-powered platform to decode the potential of the glycoproteome at clinically meaningful scale for the first time in history. The company has developed a platform capable of producing a robust pipeline of powerful clinical applications, ranging from early disease screening to diagnostics and potentially therapeutics. Founded by Nobel Laureate Dr. Carolyn Bertozzi, world-class scientist and distinguished professor Dr. Carlito Lebrilla and leading AI/ML expert Aldo Carrascoso, InterVenn will contribute to making the new era of personalized, predictive, and preventative care a reality. For more information about InterVenn, visit www.intervenn.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20230103005220/en/

CONTACT: InterVenn Contact

Ramuné Carothers

Vice President, Corporate Communications

InterVenn Biosciences

media@venn.bioInvestor Contact

David Deuchler, CFA

Gilmartin Group

ir@venn.bio

KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: RESEARCH GENERAL HEALTH MEDICAL DEVICES TECHNOLOGY HEALTH TECHNOLOGY PUBLIC RELATIONS/INVESTOR RELATIONS SCIENCE NANOTECHNOLOGY BIOTECHNOLOGY COMMUNICATIONS OTHER SCIENCE HEALTH

SOURCE: InterVenn Biosciences

PUB: 01/03/2023 08:30 AM/DISC: 01/03/2023 08:30 AM

http://www.businesswire.com/news/home/20230103005220/en